TherapeuticsMD, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
TherapeuticsMD, Inc. (TXMD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 4.00 thousand shares for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-29.
Discontinued › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2024-03-29
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2022-12-31 was 3.00K shares.
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2022-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2022-06-30 was -36.00K shares.
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2022-03-31 was 37.00K shares.
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 4.00K shares, a 96.04% decline from fiscal 2021.
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2021 was 101.00K shares, a 75.72% decline from fiscal 2020.
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2020 was 416.00K shares, a 347.31% increase from fiscal 2019.
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2019 was 93.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2022-12-31 | 3.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | 3.00K shares derived: sum of 2 quarters · filed 2024-03-29 | -33.00K shares derived: sum of 3 quarters · filed 2024-03-29 | 4.00K shares 10-K · filed 2024-03-29 | |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -36.00K shares derived: sum of 2 quarters · filed 2022-11-14 | 1.00K shares 10-Q · filed 2022-11-14 | -4.78M shares derived: sum of 4 quarters · filed 2023-04-07 | |
| 2022-06-30 | -36.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 1.00K shares 10-Q · filed 2022-08-15 | -4.78M shares derived: sum of 3 quarters · filed 2023-04-07 | -46.00K shares derived: sum of 4 quarters · filed 2023-04-07 | |
| 2022-03-31 | 37.00K shares 10-Q · filed 2022-05-16 | -4.75M shares derived: sum of 2 quarters · filed 2023-04-07 | -10.00K shares derived: sum of 3 quarters · filed 2023-04-07 | ||
| 2021-12-31 | -4.78M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-07 | -47.00K shares derived: sum of 2 quarters · filed 2023-04-07 | 101.00K shares 10-K · filed 2023-04-07 | 5.05M shares 10-K · filed 2022-03-23 | |
| 2021-09-30 | 4.74M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | 4.88M shares 10-Q · filed 2021-11-12 | |||
| 2021-06-30 | 148.00K shares 10-Q · filed 2021-08-04 | ||||
| 2020-12-31 | 416.00K shares 10-K · filed 2022-03-23 | ||||
| 2019-12-31 | 93.00K shares 10-K · filed 2022-03-23 | ||||
| 2015-09-30 | -15.96K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | -21.75K shares derived: sum of 2 quarters · filed 2015-11-05 | -136.33K shares 10-Q · filed 2015-11-05 | ||
| 2015-06-30 | -5.79K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | -120.38K shares 10-Q · filed 2015-08-07 | |||
| 2015-03-31 | -114.58K shares 10-Q · filed 2015-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |